Spironolactone vs. Winlevi for Hormonal Acne: Oral vs. Topical Comparison [2026]

Oral spironolactone is generally more effective than topical Winlevi (clascoterone 1%) for moderate-to-severe adult female hormonal acne, achieving an 82% clinical improvement rate in trials. However, Winlevi provides targeted androgen blockage directly at the skin without systemic side effects, making it a viable alternative for men, adolescents, or women seeking a non-oral option.

Affiliate Disclosure: PrescribedGlow is supported by our readers. When you purchase prescription treatments through links on our site, we may earn an affiliate commission at no extra cost to you.

Clinical Feature	Oral Spironolactone	Winlevi (Clascoterone 1% Cream)
Drug Classification	Oral potassium-sparing aldosterone & androgen antagonist	Topical androgen receptor inhibitor
Delivery Route & Frequency	Oral tablet once or twice daily (typically 50–100 mg)	Topical cream applied twice daily to affected skin
Mechanism of Action	Systemic androgen receptor blockade & suppressed ovarian androgen synthesis	Local competitive binding to androgen receptors in sebaceous glands
FDA Approval Status	FDA-approved for hypertension & edema (used off-label for acne)	FDA-approved specifically for acne vulgaris in patients 12 and older
Gender Suitability	Females only; strictly contraindicated in males	Both males and females aged 12 and older
Clinical Success Rates	82% patient-reported improvement at 24 weeks (SAFA trial)	18.4%–20.3% treatment success at 12 weeks (Phase III trials)
Primary Side Effects	Diuresis (frequent urination), menstrual spotting, breast tenderness, dizziness	Mild local skin reactions (erythema, scaling, pruritus, dryness)
Pregnancy & Nursing	Contraindicated (risk of feminization of male fetuses)	Not recommended during pregnancy due to limited clinical data
Retail Cash Price	$10–$25 per month for generic tablets	$550–$650 per 60g tube (no generic equivalent available)
Insured / Telehealth Cost	$0–$15 insurance copay; $15–$30/month via telehealth	$0–$90 via PhilRx copay card; $40 consult + insurance at Nurx
Storage & Handling	Standard room temperature; long shelf life	Refrigerated unopened; discard 30 days after opening at room temperature

Is Winlevi better than spironolactone for hormonal acne?

No, oral spironolactone demonstrates higher clinical efficacy and lesion reduction than topical Winlevi for persistent hormonal acne in women. While spironolactone systemically suppresses androgenic activity throughout the body to prevent deep cystic breakouts, Winlevi offers targeted, localized androgen receptor inhibition with a 19.9% pooled Phase III success rate, making it best for mild-to-moderate breakouts or non-systemic candidates.

Adult female acne is a widespread chronic condition driven by hormonal fluctuations. In an epidemiological study published in the Journal of the American Academy of Dermatology (Collier et al., 2008, PMID 17945383), clinical acne was documented in 50.9% of women aged 20–29, 35.2% of women aged 30–39, and 26.3% of women aged 40–49. For these women, cyclical spikes in circulating androgens trigger excessive sebum production along the lower third of the face, chin, and jawline, resulting in painful, deep-seated inflammatory nodules.

For adult women experiencing moderate-to-severe hormonal acne, oral spironolactone remains the clinical benchmark. In the landmark pragmatic Phase III SAFA trial published in The BMJ (Santer et al., 2023, PMID 37192767), 82% of adult women treated with oral spironolactone reported significant acne improvement at 24 weeks compared to 63% on placebo. Furthermore, a systematic review and meta-analysis published in the Journal of Cosmetic Dermatology (Ghanem et al., 2025, PMID 40823723) demonstrated that women receiving oral spironolactone had 6.59-fold higher odds of objective acne clearance than placebo-treated controls.

By contrast, Winlevi (clascoterone 1% cream) is a topical androgen receptor inhibitor. In two pivotal Phase III trials published in JAMA Dermatology (Hebert et al., 2020, PMID 32320027), twice-daily clascoterone achieved treatment success rates of 18.4% and 20.3% at 12 weeks (compared to 9.0% and 6.5% for vehicle cream), alongside absolute inflammatory lesion reductions of -19.3 and -20.0 lesions. While Winlevi represents a valuable non-systemic innovation, its absolute clearance percentages fall well below the systemic disease control provided by oral spironolactone.

Is Winlevi just topical spironolactone?

No, Winlevi is not topical spironolactone. Winlevi’s active molecule is clascoterone (cortexolone 17α-propionate), a patented, FDA-approved steroidal anti-androgen that skin esterase enzymes rapidly break down into inactive cortexolone. In contrast, topical spironolactone is a distinct chemical entity prepared solely by compounding pharmacies without formal FDA approval, exhibiting different absorption kinetics and formulation characteristics.

Many patients confuse the two medications because both belong to the anti-androgen category. However, clascoterone was synthesized specifically for topical delivery. Its chemical structure features a propionate ester that allows rapid penetration through the lipid bilayer of sebaceous glands. Once inside the dermal layers, endogenous esterase enzymes quickly cleave clascoterone into cortexolone—a biologically inert natural steroidal precursor. This rapid local degradation prevents the drug from building up active systemic concentrations in the bloodstream.

Topical spironolactone, on the other hand, is an unapproved compounded preparation. Dermatologists and specialized telehealth platforms like Curology often compound spironolactone into custom topical creams (typically at 5% concentrations) paired with ingredients like tretinoin or azelaic acid. In a systematic review of 14 studies published in the Archives of Dermatological Research (Farrag et al., 2025, PMID 39891744), topical spironolactone 5% demonstrated statistically significant reductions in both inflammatory lesion counts and the Acne Severity Index without inducing systemic hormonal shifts. While compounded topical spironolactone offers an affordable alternative, Winlevi remains the only FDA-approved topical androgen blocker.

What are the side effects of Winlevi vs. spironolactone?

Oral spironolactone causes systemic side effects including frequent urination, menstrual irregularities, dizziness, breast tenderness, and fatigue due to its diuretic mechanism and full-body androgen receptor antagonism. Conversely, Winlevi produces almost zero systemic side effects because it breaks down rapidly within skin tissue, with adverse events limited to mild local erythema, scaling, and dryness.

Because oral spironolactone acts as a potassium-sparing diuretic throughout the kidneys and circulatory system, it causes the body to dump sodium and fluid while retaining potassium. Common patient-reported side effects include:

• Diuresis and dehydration: Increased frequency of urination, mild lightheadedness, and postural dizziness.
• Menstrual disruption: Breakthrough spotting, irregular cycle timing, or amenorrhea caused by altered progesterone and estrogen receptor ratios.
• Breast tenderness: Mild mastalgia and localized swelling.
• Gender restriction: Oral spironolactone is strictly contraindicated in men due to severe systemic anti-androgenic effects, including gynecomastia (breast tissue growth), testicular atrophy, reduced sperm count, and erectile dysfunction. It is also contraindicated during pregnancy due to the risk of abnormal external genitalia development in male fetuses.

Winlevi circumvents these systemic vulnerabilities entirely. In a 12-month open-label safety study published in the Journal of Drugs in Dermatology (Eichenfield et al., 2023, PMID 37556524), treatment-emergent adverse events occurred in only 18.1% of patients over an entire year of twice-daily use. The observed side effects were almost exclusively mild, localized skin reactions:

• Erythema (redness): Seen in 7% to 12% of patients during early application.
• Local peeling and dryness: Reported in under 10% of users, easily managed with non-comedogenic moisturizers.
• Zero systemic anti-androgenic effects: No cases of gynecomastia, menstrual cycle alterations, or clinically relevant potassium imbalances were observed across 600 evaluated subjects.

Can you use Winlevi and spironolactone together?

Yes, dermatologists routinely combine oral spironolactone with topical Winlevi for patients with stubborn, treatment-resistant hormonal acne. Because oral spironolactone reduces systemic androgen production while Winlevi competitively blocks remaining androgens at the sebaceous follicle receptor level, combining them provides dual-action suppression of excess sebum and often allows clinicians to prescribe lower oral spironolactone doses.

In clinical practice, treating severe adult acne vulgaris frequently requires targeting multiple pathogenic pathways simultaneously. The updated clinical management guidelines published by the American Academy of Dermatology in the Journal of the American Academy of Dermatology (Reynolds et al., 2024, PMID 38300170) highlight the therapeutic value of multi-modal care that combines anti-androgens with complementary topical therapies.

When spironolactone and Winlevi are co-prescribed, clinicians typically recommend a straightforward daily routine:

1. Morning routine: Wash with a gentle, non-foaming cleanser. Apply a thin layer of Winlevi 1% cream to clean, dry skin. Follow with a barrier-repair moisturizer and a broad-spectrum mineral or chemical sunscreen (SPF 30 or higher).
2. Evening routine: Cleanse face thoroughly. Apply Winlevi 1% cream to affected areas. If you are also using a prescribed retinoid like tretinoin, wait 10 minutes for Winlevi to absorb before layering your retinoid, or alternate nights if peeling occurs.
3. Oral medication timing: Take your prescribed oral spironolactone tablet with a meal (such as dinner or breakfast) to enhance absorption and minimize stomach upset.

This combination is especially helpful for women who cannot tolerate higher spironolactone doses (such as 100 mg to 150 mg daily) due to low blood pressure or menstrual spotting, allowing them to remain comfortably on 25 mg or 50 mg while Winlevi handles localized follicular receptor blockade.

How much do Winlevi and spironolactone cost online?

Generic oral spironolactone is remarkably economical, priced at $10 to $25 monthly for cash prescriptions or $15 to $30 through telehealth platforms like Nurx and Hers. Conversely, brand-name Winlevi has no generic alternative and retails between $550 and $650 per tube, though commercially insured patients can access $0 to $90 copays through PhilRx.

Because Winlevi is a patented single-source brand, retail pricing is one of its primary barriers. Furthermore, Winlevi carries a strict storage limitation: while unopened tubes are refrigerated at pharmacies, patients store the tube at room temperature and must discard any remaining cream 30 days after opening. Patients therefore require a fresh 60-gram tube every month, meaning an uninsured patient paying retail cash would face over $6,600 in annual medication expenses.

Fortunately, modern teledermatology services and pharmacy savings programs help bridge this affordability gap:

Telehealth Platform	Medication Offered	Estimated Monthly Cost	Insurance & Prescribing Pathway
Nurx	Oral Spironolactone & Brand Winlevi 1%	Spironolactone: $15–$30/mo; Winlevi: $0–$90/mo with insurance	$40 annual medical fee; bills commercial insurance directly; coordinates with PhilRx mail order
Curology	Compounded Topical Spironolactone	$29.95/month ($59.90 billed bimonthly)	Cash-pay compounding model; avoids retail pharmacy copays; 30-day trial ($5.45 shipping)
Hers	Oral Spironolactone Tablets	$30–$40/month (multi-month plan)	Cash-pay subscription; no insurance required; free home delivery
Honeydew Care	Oral Spironolactone & Brand Winlevi 1%	$40–$60/month membership fee + Rx copays	Board-certified dermatologists; processes commercial insurance; routes Winlevi via PhilRx
Ro Derm	Oral Spironolactone & Custom Topicals	$35–$44/month	Cash-pay custom compounding and digital prescription management

For commercially insured patients, having a provider send a Winlevi prescription to the PhilRx specialty mail-order pharmacy automatically applies the manufacturer copay savings card, reducing the out-of-pocket price to $0 to $90 per tube. However, patients on Medicare, Medicaid, or TRICARE are excluded from manufacturer coupons by federal law. In contrast, oral spironolactone tablets can be filled at virtually any local pharmacy with standard insurance copays as low as $0 to $10, or with GoodRx coupons for under $15 without insurance. For more details on telemedicine prescription workflows, read our guide on how online telehealth skincare works.

Frequently asked questions

Is Winlevi stronger than spironolactone for hormonal acne? No, oral spironolactone is clinically stronger than Winlevi for moderate-to-severe hormonal acne. Because spironolactone acts systemically to decrease overall androgen synthesis and block receptor activity throughout the body, it delivers higher complete clearance rates (82% improvement in the SAFA trial) than topical clascoterone (18% to 20% trial success).

Is Winlevi just topical spironolactone? No, Winlevi is not topical spironolactone. Winlevi’s active pharmaceutical ingredient is clascoterone (cortexolone 17α-propionate), an FDA-approved prescription chemical entity that skin esterases break down into inactive cortexolone. Topical spironolactone is a chemically separate compound available only through specialized compounding pharmacies without standalone FDA approval.

Can you use Winlevi and spironolactone together? Yes, dermatologists frequently combine oral spironolactone with topical Winlevi for persistent or severe hormonal acne. This combined approach blocks androgens both systemically in the bloodstream and locally inside sebaceous glands, often allowing providers to prescribe lower oral spironolactone doses to minimize diuretic and menstrual side effects.

Can men take spironolactone or use Winlevi? Men can safely use Winlevi, but should not take oral spironolactone. Winlevi acts locally in the skin and is FDA-approved for males aged 12 and older with zero risk of feminization. Oral spironolactone blocks androgens systemically in men, frequently causing breast tissue enlargement (gynecomastia), loss of libido, and erectile dysfunction.

How long does it take for Winlevi vs spironolactone to clear acne? Both medications require patience. Initial reductions in skin oiliness and inflammation appear within 4 to 6 weeks for both therapies. However, maximum clinical clearance typically requires 12 weeks for Winlevi (clascoterone 1%) and 16 to 24 weeks of consistent daily dosing for oral spironolactone.

Why is Winlevi so much more expensive than spironolactone? Oral spironolactone is a generic medication manufactured by multiple companies for decades, costing $10 to $25 per month. Winlevi is a patented, first-in-class brand-name drug with no generic equivalent, carrying a retail cash price of $550 to $650 per tube unless lowered by commercial insurance or manufacturer copay programs.

Bottom line

Oral spironolactone remains the overall winner for adult women dealing with moderate-to-severe hormonal acne, supported by decades of clinical evidence, an 82% patient satisfaction rate in the SAFA trial, and an affordable generic price of $10 to $30 per month. For adult females with deep, cyclical cystic breakouts along the jawline, oral spironolactone provides systemic hormonal control that topical treatments alone struggle to replicate. (For an in-depth look at dosage, timelines, and potassium guidelines, read our dedicated spironolactone for acne guide).

However, Winlevi (clascoterone 1% cream) is a vital clinical advance for patients who cannot or prefer not to take systemic pills. As a localized topical androgen receptor inhibitor, Winlevi offers targeted oil suppression with zero risk of menstrual disruption, potassium changes, or feminizing side effects, making it suitable for men, adolescents, and women seeking non-systemic hormonal care. If you have commercial health insurance to utilize the PhilRx copay program, Winlevi is an outstanding topical cornerstone. (Learn more in our standalone clascoterone for acne guide).

Get Winlevi & Spironolactone at Nurx → · Read our Nurx review → · Try Custom Acne Compounding at Curology → · Read our Curology review → · Hormonal Acne Hub → · Acne Treatment Guide →

---

Sources

• Santer M, Lawrence M, Renz S, et al. Effectiveness of spironolactone for women with acne vulgaris (SAFA): a pragmatic, multicentre, phase 3, double blind, randomised controlled trial. The BMJ. 2023;381:e074349. PMID: 37192767. https://pubmed.ncbi.nlm.nih.gov/37192767/
• Ghanem L, et al. Efficacy and safety of spironolactone in adult female acne: A systematic review and meta-analysis of randomized controlled trials. Journal of Cosmetic Dermatology. 2025. PMID: 40823723. https://pubmed.ncbi.nlm.nih.gov/40823723/
• Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized chemical trials. JAMA Dermatology. 2020;156(6):621-630. PMID: 32320027. https://pubmed.ncbi.nlm.nih.gov/32320027/
• Eichenfield LF, Hebert A, Stein Gold L, et al. Open-label, long-term extension study to evaluate the safety of clascoterone cream 1% in patients with acne vulgaris. Journal of Drugs in Dermatology. 2023;22(8):792-800. PMID: 37556524. https://pubmed.ncbi.nlm.nih.gov/37556524/
• Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. Journal of the American Academy of Dermatology. 2008;58(1):56-59. PMID: 17945383. https://pubmed.ncbi.nlm.nih.gov/17945383/
• Farrag M, et al. Topical spironolactone for acne vulgaris: a systematic review and meta-analysis. Archives of Dermatological Research. 2025;317(1):112. PMID: 39891744. https://pubmed.ncbi.nlm.nih.gov/39891744/
• Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. 2024;90(5):1006.e1-1006.e30. PMID: 38300170. https://pubmed.ncbi.nlm.nih.gov/38300170/